June 10, 2020 / 9:23 PM / a month ago

BRIEF-Alnylam Announces Publication Of Phase 3 Study Results For Givosiran In The New England Journal Of Medicine

June 10 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM ANNOUNCES PUBLICATION OF ENVISION PHASE 3 STUDY RESULTS FOR GIVOSIRAN IN THE NEW ENGLAND JOURNAL OF MEDICINE

* ALNYLAM PHARMA - GIVOSIRAN DEMONSTRATED SIGNIFICANT REDUCTION IN RATE OF PORPHYRIA ATTACKS COMPARED WITH PLACEBO IN PATIENTS WITH AHP

* ALNYLAM PHARMA - IMPROVEMENTS IN NUMBER OF SECONDARY ENDPOINTS INCLUDING REDUCTIONS IN URINARY ALA & PBG LEVELS, DAYS OF INTRAVENOUS HEMIN USE

* ALNYLAM PHARMACEUTICALS - IN ALL PATIENTS WITH AHP, MEAN AAR WAS SIGNIFICANTLY REDUCED BY 73% RELATIVE TO PLACEBO

* ALNYLAM PHARMA - PATIENTS TREATED WITH GIVOSIRAN REPORTED FAVORABLE EFFECTS ON EXPLORATORY ENDPOINTS RELATED TO USE OF ANALGESICS, OVERALL HEALTH STATUS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below